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We previously reported that DA-9601, ethanol herbal 
extract of Artemisia asiatica, inhibited histamine and 
leukotriene releases in guinea pig lung mast cells acti-
vated with specific antigen/antibody reaction. This 
study aimed to evaluate the inhibitory effect of DA-
9601 on the OVA-induced airway inflammation in al-
lergic asthma mouse model. BALB/c mice were sensi-
tized and challenged with OVA. DA-9601 was adminis-
tered orally 1 h before every local OVA-challenge. 
OVA-specific serum IgE was measured by ELISA, re-
cruitment of inflammatory cells in BAL fluids and 
lung tissues by Diff-Quik and H&E staining, respec-
tively, the expressions of CD40, CD40L and VCAM-1 
by immunohistochemistry, goblet cell hyperplasia by 
PAS staining, activities of MMPs by gelatin zymogra-
phy, expressions of mRNA and proteins of cytokines 
by RT-PCR and ELISA, activities of MAP kinases by 
western blot, and activity of NF-κB by EMSA. DA-
9601 reduced IgE level, recruitment of inflammatory 
cells into the BAL fluid and lung tissues, expressions of 
CD40, CD40L and VCAM-1 molecules, goblet cell hy-
perplasia, MMPs activity, expressions of mRNA and 
productions of various cytokines, activities of MAP 
kinases and NK-κB increased from OVA-challenged 
mice. These data suggest that DA-9601 may be devel-
oped as a clinical therapeutic agent in allergic diseases 
due to suppressing the airway allergic inflammation 
via regulation of various cellular molecules expressed 
by MAP kinases/NF-κB pathway. 
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Introduction 
 
There are difficulties in the drug development process be- 
cause of the limited understanding of molecular pathogene- 
sis of various diseases. Therefore, this has produced a trend  
toward newly discovered compounds that are used in clinic  
rather than to develop new compounds. DA-9601 has been  
used to treat gastric ulcer (Hahm et al., 2001; Huh et al.,  
2003) as newly discovered compound. DA-9601 is the  
formulated ethanol extract of Artemisia asiatica Nakai (As- 
teraceae) and it contains the pharmacologically active fla- 
vonoid, eupatilin (Seo and Surh, 2001). Moreover, eupatilin 
has been reported to have anti-oxidative and antiinflamma-
tory effects on experimentally induced gastrointestinal, he-
patic and pancreatic damage (Lee et al., 2001). Our labora-
tory previously reported that eupatilin blocks multi-signal 
pathways and Ca2+ influx in the mast cells activated by spe-
cific antigen/antibody reaction (Kim et al., 2005). 
Allergic asthma is a chronic and complex inflammatory 
disease of the lung characterized by reversible obstruction 
of airway, hyper-responsiveness (AHR), infiltration of in-
flammatory cells into lung tissues, mucus overproduction 
(Kon and Kay, 1999), the overexpressions of Th2-mediated 
cytokines including IL-4, IL-5, IL-13 and TNF-α, and 
chemokines such as eotaxin and RANTES in the airways of 
allergic asthmatics (Kon and Kay, 1999; Renauld, 2001;  
 
Abbreviations: BAL, bronchial alveolar lavage; ERK, extracellular 
signal-regulated kinase; HPMC, hydroxypropylmethyl-cellulose; 
JNK, c-Jun NH2-terminal kinase; NF-κB, nuclear factor-kappa B; 
OVA, chicken ovalbumin. 
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Zimmermann et al., 2003). The recruitment of inflamma- 
tory cells requires the expression of adhesion molecules 
such as ICAM-1 and VCAM-1 (Ohkawara et al., 1995; 
Wills-Karp and Karp, 2004). The release of Th2-mediated 
cytokines also causes persistent inflammatory cell recruit-
ment and induces structural changes in airway walls, such 
as, increased basement membrane thickness, increased col-
lagen deposition, smooth muscle hypertrophy, and goblet 
cell hyperplasia (Chiapara et al., 2001). Moreover, these 
clinical features are accompanied by an underlying in-
flammatory pathology and airway remodeling, and these 
pathological changes are known to contribute to the clinical 
symptoms of allergic diseases. 
Based on the described above, a potent anti-allergic 
agent is needed with a pronounced anti-inflammatory effect 
and minimal toxicity to treat allergic diseases. And, oral 
administration may reduce its toxicity and risk in utility, 
compared to routes of other administration. Therefore, we 
examined for the first time whether DA-9601 newly devel-
oped and administrated orally suppresses airway inflamma-
tion in OVA-induced allergic asthma mice. 
 
 
Materials and Methods 
 
Sensitization and antigen challenge protocol Specific pathogen 
free female BALB/c mice, 6−8 week old, were divided by six 
groups (8 mice/group). Con (negative control), mice sensitized 
and challenged with phosphate buffered saline (PBS); G, mice 
sensitized with OVA and challenged with PBS (general sensitiza-
tion); OVA, mice sensitized and challenged with OVA (OVA-
challenged mice); GL30, mice treated with 30 mg/kg DA-9601 1 
h before every OVA challenge (nebulization); GL100, mice 
treated with 100 mg/kg DA-9601 1 h before every OVA chal-
lenge. Mice were sensitized with 10 μg ovalbumin (OVA, Grade 
V; Sigma-Aldrich, USA) adsorbed in 250 μg/200 μl of alum 
(aluminum hydroxide, 2% Alhydrogel; Superfos Biosector, Den-
mark) by intraperitoneal (i.p.) injection on days 0, 5, 14, 21, and 
28 (general sensitization). One week (day 35) after the final injec-
tion, mice were challenged with 2% OVA for 10min once daily 
for 7 consecutive days until day 41 (local challenge). On day 49 
mice were challenged with 2% OVA for 10 min (OVA- 
challenged mice), and mice were sacrificed on day 50. 
 
Treatment protocol DA-9601 (30 or 100 mg/kg) (Dong-A 
Pharmaceutical Co. Ltd., Korea) was dissolved in 3% hydro-
xypropylmethylcellulose (HPMC) (Sigma-Aldrich, USA) solu-
tion (5 ml) and administered orally for 7 consecutive day 1h 
before every local challenge (from day 35 to day 41). In order to 
examine the effect of HPMC solution (the DA-9601 solvent), 
HPMC was orally administrated instead of DA-9601 1 h before 
every local challenge. DA-9601 was administrated 1 h before 
every local challenge because it has a half-life (t1/2) of 1 h in 
vivo. All animal experiments were conducted in the Laboratory 
Animal Research Center of Sungkyunkwan University and were 
approved by the Association for the Assessment and Accredita-
tion of Laboratory Animal Care (AAALAC).  
 
Serum collection and analysis of serum OVA-specific IgE an-
tibody levels After anesthesia, blood was collected by cardiac 
puncture. Blood was allowed to clot for 30 min, centrifuged at 
900 × g for 30 min, and then analyzed for OVA-specific IgE anti-
body level by ELISA (Lee et al., 2004a). For OVA-specific IgE, 
microplates were coated with purified rat anti-mouse IgE, and 
then treated with mouse sera followed by biotinylated OVA pre-
pared using a peroxidase-conjugated goat anti-biotin antibody, 
which was used as secondary antibody. Reactions were read using 
an ELISA plate reader at 415 nm. Mouse IgE (BD Biosciences, 
USA) was used for calibrating the assay. 
 
Collection and analysis of bronchoalveolar lavage (BAL) fluid  
cells After blood collection, tracheas were exposed by cannulating  
upper tracheas and BAL fluid was collected by lavaging twice  
with 1 and 0.8 ml of PBS (85−90% of the input volumes were  
recovered). Collected lavage fluid was centrifuged at 400 × g for  
5 min at 4°C. Briefly, after centrifugation, lavage supernatants  
were used for matrix matalloproteinases (MMPs) activities and  
total viable cell numbers in pellets were determined by trypan  
blue exclusion using a hematocytometer. BAL cells in pellets  
were adjusted to 5 × 105 cells/ml in PBS for different cell counting.  
Cytospin preparations were made using a Cytospin III (Shandon,  
USA), and then stained with Diff-Quik (International Reagents 
Corp., Japan). Differential cell counting was performed using  
standard morphological criteria (McKay et al., 2004).  
 
Zymography MMPs activities in BAL fluid supernatant was 
performed as described previously (Kumagai et al., 1999; 
McMillan et al., 2004). The first BAL fluid samples (35 μl) 
collected were loaded onto 7.5% polyacrylamide gels containing 
10 mg/ml gelatin (Sigma-Aldrich, USA), in the presence of SDS 
under nonreducing conditions. After electrophoresis, gels were 
washed three times for each 15 min in 20 mM Tris/HCl (pH 7.8) 
containing 2.5% Triton X-100, and then repeatedly washed 
twice for 15 min in developing buffer [20 mM Tris/HCl (pH 
7.8), 1.0% Triton X-100, 10 mM CaCl2, and 5 µM ZnCl2]. After 
washing, gels were incubated in developing buffer at 37°C for 
18 h, stained with 0.25% Coomassie Brilliant Blue R-250 (Bio-
Rad, USA), destained in a solution of 10% acetic acid contain-
ing 40% methanol, dried, and analyzed with a LAS1000 Image 
Reader (Fuji film, Japan). Gelatinolytic activity was detected as 
a clear band against a blue background. Human MMP-2 and 
MMP-9 (Chemicon, USA) were used as gelatinase zymography 
standard markers. 
 
Lung histology After BAL, lungs were perfused with 5 ml PBS via 
the right ventricle. Exsanguinated left lungs were then removed 
from the chest cavity and fixed in 4% paraformaldehyde. Lobes 
were isolated, embedded in paraffin, and sectioned at 3 μm. Tissue 
sections were stained with H & E for general morphology (McKay 
et al., 2004) and with periodic acid-Schiff (PAS) reaction for goblet 
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cell identification in airway epithelium (Edwan et al., 2004). Num-
bers of goblet cell hyperplasia were quantified in percentage of 
PAS-positive cells/total cells in 50 μm × 50 μm area by microscopy. 
Removed right lung tissues were stored at –70°C for determinations 
of cytokine mRNA and protein expressions. 
 
Immunohistochemistry for CD40, CD40L or VCAM-1 ex-
pressions Immunohistochemistry was conducted using a modi-
fication of the method described previously (Burgess et al., 
2005; Ohkawara et al., 1995). Sections (μm) in paraffin-
embedded sections were deparaffinized with xylene and then 
rehydrated. Slides were incubated in 3% hydrogen peroxide for 
5min to quench endogenous peroxidase activity, blocked with 
PBS containing 1% BSA for 1 h, and then incubated with anti-
CD40 or anti-CD40L antibody (1:25 dilution, Lab Vision, USA) 
or anti-VCAM-1 (1:50 dilution, Santa Cruz biotechnology, 
USA) in blocking solution at 4°C for 24 h. After washing in 
PBS, slides were treated with biotinylated secondary antibody 
for 10 min, streptavidin-HRP (horse radish peroxidase) for 10 
min, DAB chromogen substrate for 5−10 min (DAKO, USA) 
and counterstained with hematoxylin (Sigma-Aldrich, USA), 
and finally mounted using aqueous mounting medium. 
 
Cytokine levels in lung tissues The levels of IL-4, IL-5, IL-13, and  
TNF-α in supernatants isolated from lung tissue homogenates were  
determined by ELISA (McMillan et al., 2004). Standard curves  
were generated using different concentrations of recombinant cyto- 
kines. The limit of detection was at least 7.8 pg/ml. 
 
Quantification of cytokine mRNAs in lung tissues by RT-
PCR Cellular RNAs were extracted using TRIZOL reagent 
(Invitrogen, USA). Briefly, TRIZOL reagents (1 ml) were added 
to 50 mg of lung tissues, and homogenized using a Polytron 
(Kinematica, Switzerland). Two hundred microliters of chloro-
form were added to the homogenates, and these were then incu-
bated for 10 min at room temperature. After centrifugation at 
10,600 × g for 15 min, an equal volume of isopropyl alcohol 
was added. The samples were then incubated for 10 min at room 
temperature and centrifuged at 10,600 × g for 10 min. RNA 
pellets were washed with 75% ethanol and dried. RT-PCR was 
performed in a final volume of 25 μl using a SuperScript One-
step RT-PCR kit (Invitrogen, USA) in automated thermal cycler 
(GeneAmp PCR system 9700, Perkin Elmer, USA). PCR assays 
were performed for 35 cycles. Each cycle consisted of the fol-
lowing step: denaturation at 94°C for 30 s, annealing at 56°C for 
45 s, and extension at 72°C for 1 min. PCR products were ana-
lyzed in 1.7% agarose gel containing ethidium bromide (EtBR) 
(Picado et al., 2003).  
 
Assay of MAP kinases by Western blot Lung tissues (30 
mg/50 μl lysis buffer) were homogenized in low-salt lysis buffer 
[10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM 
EGTA, 1 mM DTT, 0.5 mM PMSF, 2.0 μg/ml aprotinin, 2.0 
μg/ml leupeptin] using a Polytron (Kinematica, Switzerland), 
and allowed to swell on ice for 10 min. Cell lysates (μg) were 
subjected to 10% SDS-PAGE and transferred to PVDF mem-
brane (Schleicher & Schuell, Germany). Membranes were washed 
with TBS containing 0.1% Tween 20 (TBST), and then blocked 
for 1 h in TBST containing 5% skim milk. After washing the 
membranes with TBST, they were treated with antibodies 
against ERK, JNK, p38 (Santa Cruz Biotechnology, Inc., USA) 
and p-ERK, p-JNK, p-p38 (Cell Signaling, USA) diluted with 
TBST (1:1,000) and incubated for 60 min at RT. Membranes 
were washed with TBST, and treated with HRP-conjugated goat 
anti-mouse or HRP-conjugated rabbit anti-goat IgG (diluted to 
1:5,000−1:10,000) (Zymed Laboratory Inc., USA) in TBST for 
60min. After washing, the protein bands were visualized using 
ECL solution (Amersham Biosciences UK Limited, little Chal-
font Buckinghamshire, UK). 
 
Preparation of nuclear extract The activity of NF-κB in su-
pernatants isolated from lung tissue homogenates were deter-
mined by EMSA (Desmet et al., 2004; Picado et al., 2003). 
Lung tissues (30 mg/500 μl lysis buffer) were homogenized in 
low-salt lysis buffer [10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 
mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 2.0 
μg/ml aprotinin, 2.0 μg/ml leupeptin] using a Polytron (Kine-
matica, Switzerland), and allowed to swell on ice for 10 min. 
Ten percent of Nonidet P-40 was then added and nuclei were 
pelleted by centrifugation at 20,800 × g for 1 min. Nuclear pel-
lets were lysed in 40 μl of nuclear lysis buffer [20 mM HEPES 
(pH 7.9), 420 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM 
MgCl2, 20% glycerol, 1 mM DTT, 0.5 mM PMSF, 2 μg/ml 
aprotinin, 2 μg/ml leupeptin], and incubated on ice for 30 min. 
The nuclear extract (supernatant) was retained after centrifuging 
at 15,300 × g for 10 min at 4°C.  
 
Electromobility shift assay The consensus oligonucleotide of 
NF-κB (3.5 pmol) (Promega, USA) was radiolabeled using 10 
μCi of [γ-32P] ATP. Labeled probes were then separated from 
unincorporated isotope by size exclusion chromatog-raphy using 
Microspin G-25 Columns (Amersham Biosciences, USA). Nuclear 
extracts (5 μg) were mixed with binding buffer (3 μl) and incubated 
for 10 min at room temperature (final volume 15 μl). The mixture 
was then added a labeled probe (1 μl, 300,000 cpm) and incubated 
for 20 min at room temperature. Ten microliters of binding reaction 
mixture were loaded onto 6% polyacrylamide gel and run at 150 V 
for 30 min. Gels were dried and NF-κB bands were analyzed by 
phosphoimaging using FLA-2000 (Fuji Film, Japan). 
 
Statistical analysis Experimental data are presented as means ± 
S.E.M. Data were analyzed by two-way analysis of variance 
(ANOVA) with multiple comparisons. P values of < 0.05 were 
regarded as significant. 
 
 
Results 
 
Inhibition of serum OVA-specific IgE production by 
DA-9601 In order to examine whether DA-9601 influenced  
 Ji Young Kim et al. 107 
 
Table 1. Effects of DA-9601 on serum IgE antibody levels in 
OVA-challenged allergic asthma mouse modela. 
 Serum IgE Ab (ng/ml) 
Control 
G 
OVA 
OVA with HPMC 
GL30 
GL100 
000.5 ± 1.34 
135.1 ± 5.42*** 
192.2 ± 15.13***,# 
182.1 ± 13.31***,# 
139.5 ± 4.04 (25.4)++ 
123.2 ± 9.64 (34.2)+++ 
a 
BALB/c mice were sensitized and challenged with OVA as described 
in Materials and Methods. Control, mice sensitized and nebulized 
with PBS; G, mice sensitized with OVA and challenged with PBS; OVA, 
mice sensitized and challenged OVA (OVA-challenged group); OVA 
with HPMC, OVA-challenge plus HPMC mice (positive control); GL30 
or GL100, mice treated with 30 mg/kg or 100 mg/kg DA-9601 1 h 
before every local challenge. Parentheses were expressed as a decreas-
ing percentage evoked by DA-9601 administration, versus OVA-
challenged mice. Eight animals were assigned to each group. *** P < 
0.001 versus the control; 
#
 P < 0.05 versus general sensitization (G); 
++
 P 
< 0.01; 
+++
 P < 0.001 versus OVA-challenged mice (OVA-challenged 
group) or OVA with HPMC. 
 
 
OVA-specific IgE production in allergic mouse model,  
OVA-specific IgE antibody levels were measured by  
ELISA (Table 1). DA-9601 administration reduced serum  
OVA-specific IgE level increased in OVA-induced allergic  
mice, but did not completely. HPMC administrated mice  
had no effect in OVA-challenged mice. 
 
Reduction in the recruitment of inflammatory cells in 
BAL fluids by DA-9601 We examined the effect of DA-
9601 on the infiltration of inflammatory cells into BAL 
fluids in OVA-challenged mice. The OVA-challenged 
mice showed a significant increase in total cell numbers, 
as compared with PBS-treated control. The order of in-
crease of inflammatory cells was: eosinophils, lympho-
cytes, neutrophils, and macrophages. The administration 
of DA-9601 significantly reduced the number of total 
cells, eosinophils, neutrophils, and lymphocytes recruited 
in dose-dependent manner (Table 2). These results indi-
cate that DA-9601 blocks the migration of inflammatory 
cells into the bronchial lumens of OVA-challenged mice. 
OVA-challenged mice with HPMC (solvent of DA-9601) 
produced similar results in OVA-challenged mice without 
HPMC. 
 
Histopathologic examinations of lung tissues treated 
with DA-9601 We investigated inflammatory cell re-
cruitment into the lung tissues of OVA-challenged allergic 
mice. In these mice we observed inflammatory cell re-
cruitment into the surrounding peribronchial and perivas-
cular areas, and epithelial thickening (Fig. 1A-c). Al-
though 30 mg/kg of DA-9601 reduced inflammatory cell 
recruitment and epithelial thickening (Fig. 1A-e), a high 
dose of DA-9601 (100 mg/kg) completely reduced (Fig. 
1A-f). And, no significant changes were observed in OVA-
challenged mice with HPMC (Fig. 1A-d). 
In addition, many goblet cells (pink color dot) contain-
ing mucus using Periodic acid-Schiff (PAS) stain were 
increased in OVA-challenged mice (Fig. 1B-c). The num-
bers of goblet cells, which were quantified in percentage 
of PAS-positive cells/total cells in 50 μm × 50 μm area by 
microscopy, were significantly lower in DA-9601-admini-
strated mice (55.7 ± 1.60% for OVA-challenged mice; 55.9 
± 1.54% for OVA with HPMC treated mice; 21.3 ± 3.01% 
for 30 mg/kg DA9601; 6.2 ± 3.03% for 100 mg/kg 
DA9601). That is, DA-9601 (30 or 100 mg/kg) decreased 
up to 61.8% and 88.9%, respectively. 
 
Expression of CD40, CD40L or VCAM-1 in lung tis-
sues We further examined the expressions of CD40 and 
CD40L, which are involved in B and T cell activation and 
are major costimulatory molecules in B cells and antigen 
presenting cells (APCs) (Banchereau et al., 1994; Kawabe, 
1994), and also examined VCAM-1 expression, which 
directs the extravasations of different cell populations of 
leukocytes recruited to inflammatory sites (Ohkawara et 
al., 1995). DA-9601 treatment reduced CD40, CD40L 
(brown color; Figs. 2A and 2B) or VCAM-1 (brown 
color; Fig. 2C) expressions in OVA-challenged mice. 
OVA-challenged mice with HPMC did not affect the ex-
pressions of these costimulatory and adhesion molecules, 
compared to OVA-challenged mice. 
 
Expressions of cytokines mRNA and proteins in the 
lung tissues We also examined whether mRNAs and pro-
tein levels of individual inflammatory cytokines were 
changed in DA-9601-administrated mice. DA-9601 re-
duced the up-regulations of IL-4, IL-5, IL-13, and TNF-α 
mRNA in the lung tissues of OVA-challenged mice (Fig. 
3 upper panel). The protein expressions of cytokines pro-
duced (Fig. 3 lower panel) behaved in the same manner as 
their mRNA expressions. The changes of mRNA and pro-
tein expressions of these inflammatory cytokines were not 
observed in OVA-challenged mice with HPMC, compared 
to OVA-challenged mice.  
 
Activities of matrix metalloproteinases (MMPs) in BAL 
fluid or lung tissues by DA-9601 MMPs, well known 
extracellular matrix (ECM)-degrading enzymes, are up-
regulated in area showing inflammatory cell accumulation 
and area showing lung tissue remodeling (Kumagai et al., 
1999; Nagase and Woessner, 1999). Therefore, we exam- 
ined the levels of constitutive MMP-2 and inducible MMP-
9 in the BAL fluids of OVA-induced mice. The gelati-
nolytic activities of MMP-2 and MMP-9 in BAL fluids 
were elevated in OVA-challenged mice. Both MMPs ac-
tivities were reduced in dose-dependent manner (Fig. 4).
 
108 Reduction of Mouse Allergic Inflammation by DA-9601 
 
Table 2. Effect of DA-9601 on the recruitment of inflammatory cells into BAL in OVA-induced allergic asthmatic micea. 
 
Total cell 
(× 104) 
Macrophage 
(× 104) 
Lymphocyte 
(× 104) 
Neutrophil 
(× 104) 
Eosinophil 
(× 104) 
Control 02.9 ± 2.80 1.6 ± 0.17 1.4 ± 0.07 0.0 ± 0.00 0.0 ± 0.00 
G 03.0 ± 4.26 1.6 ± 0.17 1.4 ± 0.17 0.0 ± 0.00 0.0 ± 0.00 
OVA 15.3 ± 6.12 2.8 ± 0.09*** 5.1 ± 0.13*** 3.5 ± 0.24*** 3.8 ± 0.2***  
OVAb  15.4 ± 3.00 3.0 ± 0.36*** 5.3 ± 0.32*** 3.4 ± 0.05*** 3.7 ± 0.70*** 
GL30 11.7 ± 5.00 2.6 ± 0.32* + 3.2 ± 0.12***+ 2.8 ± 0.11*** + 2.2 ± 0.12*** ++ 
GL100 07.4 ± 3.00 1.8 ± 0.14++ 1.9 ± 0.15+++ 1.3 ± 0.14*** +++ 1.3 ± 0.13*** +++ 
a 
BALB/c mice were sensitized and challenged with OVA, and then BAL fluids were collected as described in Materials and Methods. BAL 
cells were separated using a Cytospin, and then stained with Diff-Quik. Differential cell counting was performed using standard morphological 
criteria. The symbols used are described in Table 1. Eight animals were assigned to each group.  
b 
OVA with HPMC. * P < 0.05; *** P < 0.001 versus the control or OVA mice; 
+
 P < 0.05; 
++
 P < 0.01; 
+++
 P < 0.001 versus the OVA-challenged 
mice or OVA with HPMC. 
 
 
A 
a        b        c 
 
 
 
d        e        f 
 
 
B 
a        b        c 
 
 
d        e         f 
 
 
 
Fig. 1. Effect of DA-9601 on histological changes in the lung 
tissues of OVA-induced allergic mice. BALB/c mice were 
sensitized and challenged with OVA as described in Materials 
and Methods. Lung tissues fixed with 10% formalin were 
sectioned and stained with haematoxylin and eosin (H&E) (A) 
or periodic acid-Schiff (PAS) (B). a (Con), mice sensitized 
and challenged with PBS alone; b, mice sensitized with OVA 
and challenged with PBS; c, mice sensitized and challenged 
with OVA (OVA-challenged mice); d, mice treated with 
HPMC alone 1 h before every local challenge; e (GL30), f 
(GL100), mice treated with 30 mg/kg (e) or 100 mg/kg (f) DA-
9601 1 h before every local challenge. Histological appear-
ances were scored for the presence of peribronchial and 
perivascular inflammation, and these scores were added to-
gether to give a total lung inflammation score (Histogram). 
Numbers of goblet cell hyperplasia were quantified in percent-
age of PAS-positive cells/total cells in 50 µm × 50 µm area by 
microscopy. Arrow in lower panel indicates goblet cells. Mag-
nification of each histological change was 400 times. *** P < 
0.001 versus the control or general sensitized mice; +++ P < 
0.001 versus OVA-challenged or OVA with HPMC mice. 
Eight animals were assigned to each group. 
A 
a        b        c 
 
 
 
d        e        f 
 
 
B 
a        b       c 
 
 
d        e        f 
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d        e        f 
 
 
 
Fig. 2. Effect of DA-9601 on CD40, CD40L, or VCAM-1 expres-
sions in the lung tissues of OVA-induced allergic mice. BALB/c 
mice were sensitized and challenged with OVA as described in 
Materials and Methods. Immunohistochemistry was carried out 
using paraffin-embedded lung tissues and primary anti-CD40 
antibody, anti-CD40L antibody (diluted 1:25) or anti-VCAM-1 
antibody (diluted 1:50) and the DAB system. (A) CD40 molecule, 
(B) CD40L molecule, and (C) VCAM-1 molecule. The other 
symbols used are described in Fig. 1. Immunohistochemical ap-
pearances were scored for the presence of molecules (Histogram). 
Magnification of each immunohistochemical changes was 200 
times. *** P < 0.001 versus the control or general sensitized 
mice; +++ P < 0.001 versus OVA-challenged or OVA with HPMC 
mice. Eight animals were assigned to each group. 
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Fig. 3. Effect of DA-9601 on cytokine mRNA expressions and 
proteins in the lung tissues of OVA-induced allergic mice. 
BALB/c mice were sensitized and challenged with OVA as de-
scribed in Materials and Methods. Each mRNA expression was 
determined using RT-PCR analysis (upper panel for each cyto-
kine). Individual cytokine levels in lung tissues were determined 
by ELISA (lower panel). The symbols used are described in Fig. 1. 
* Relative intensity versus the control and GAPDH mRNA. *** P 
< 0.001 versus the control or general sensitized mice; ++ P < 0.01, 
+++ P < 0.001 versus OVA-challenged or OVA with HPMC mice. 
Eight animals were assigned to each group. 
 
 
As the gelatinolytic activities of MMPs showed changes 
in BAL fluids (Fig. 4), the mRNA expressions of MMPs 
and tissue inhibitors of metalloproteinases (TIMPs) were 
examined in lung tissues. The mRNA levels of these spe-
cies showed no change in all groups (data not shown). 
This result may have been obtained because changes of 
MMPs and TIMPs were undetectable due to the mRNA of 
various lung tissues. However, these issues require further 
study. These data are inconsistent with the results of the 
zymography study on BAL fluids. 
 
Activities of MAP kinases by DA-9601 In a previous 
data, we found that DA-9601 reduces the expressions of 
cytokines in OVA-challenged mice. MAP kianse pathway 
has been reported to play a major role in biological re-
sponses including cytokine expressions. Therefore, we 
examined whether the phosphorylations of the three MAP 
kinases in the OVA-induced allergic mice lung tissues 
were reduced by DA-9601. DA-9601 inhibited the in-
creased level of phosphorylated MAP kinases (Fig. 5A). 
 
DNA binding activity of nuclear factor-kappa B (NF- 
 
 
 
 
 
 
 
 
Fig. 4. Effect of DA-9601 on the gelatinolytic activities of matrix 
metalloproteinases (MMPs) in the BAL fluids of OVA-induced 
asthmatic mice. MMPs in BAL fluids collected from mice as 
described in Materials and Methods were analyzed by gelatin 
zymography. Gelatinolytic activity was detected as clear bands 
against a blue background. Human MMP-2 and MMP-9 were 
used as gelatinase zymography standard markers. M, Marker. All 
symbols used are as described in Fig. 1. MMP-2, -9, matrix metal-
loproteinase-2, -9. * Relative intensity for MMP-9 versus the 
control; ** Relative intensity for MMP-2 versus the control. Eight 
animals were assigned to each group. 
 
 
κB) and AP-1 by DA-9601 We further examined whether 
DA-9601 administration influences NF-κB and AP-1 ac-
tivities in inflammatory cells of lung tissues. Nuclear ex-
tracts from OVA-induced allergic mice lung tissues showed 
increased NF-κB DNA binding activity, and DA-9601 in-
hibited this activity (Fig. 5B). However, AP-1 transcription 
factor activity was not detected in any experimental mice 
(data not shown). 
 
 
Discussion 
 
Allergic asthma is one of the most common disorders en-
countered in clinic, and the mortality associated with aller-
gic asthma has increased worldwide over the last two dec-
ades (Renauld, 2001). Therefore, it is important to under-
stand the pathogenesis of allergic asthma and to develop 
novel therapeutic agents. In our previous study, we ob-
served that eupatilin (an active component of DA-9601) 
inhibited histamine and leukotriene releases in guinea pig 
lung mast cell activation (Kim et al., 2005). Therefore, it is 
essential to examine whether DA-9601 reduces airway in-
flammatory responses in OVA-induced allergic mouse 
model. In the present study using an allergic mouse model, 
we found that DA-9601 administrated by oral, the formu-
lated ethanol extract of Artemisia asiatica, is potentially of 
use as a therapeutic agent for the treatment of allergic dis-
eases such as asthma. 
Allergen-induced airway diseases are caused by aller-
gen-specific Th2-mediated cytokines, which induce the 
development of airway inflammation, e.g., Th2 cell acti-
vation, inflammatory cells, and T/B cell involvement in Ig 
isotype switching (Kon and Kay, 1999; Renauld, 2001; 
Romagnani, 2001; Steinke and Borish, 2001; Zimmermann 
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Fig. 5. Effect of DA-9601 on MAP kinases or NF-κB activity in the 
lung tissues of OVA-induced allergic mice. MAP kinases or NF-κB 
activity were determined in protein and nuclear extracts, respec-
tively, prepared from sensitized and challenged mouse lung tissues 
as described in Materials and Methods. The symbols used are 
described in Fig. 1. A. MAP kinase activity. B. NF-κB activity. n, 
negative control; g, competition assay. * Relative intensity versus 
the control. Eight animals were assigned to each group. 
 
 
et al., 2003). Table 2 showed that DA-9601 reduced lym-
phocyte and granulocyte numbers, and thus DA-9601 ad-
ministration might induce a reduction in Th2 lymphocyte 
response. This reduced responses elicited by DA-9601 may 
affect the production and secretion of various Th2 cyto-
kines (IL-4, IL-5, IL-13, and TNF-α). In our data, DA-
9601 administration reduced cytokine mRNA (Fig. 3 up-
per panel) and protein productions (Fig. 3 lower panel), 
and inflammatory cell infiltration into BAL fluids (Table 
2) and lung tissues (Fig. 1A). 
The interaction of CD40 on B cells with CD40L-
expressing cells, mainly T cells or mast cells, is important 
for Ig isotype class switching (Banchereau et al., 1994; 
Burgess et al., 2005; Kawabe, 1994) and plays a central 
role in the induction of allergen-mediated airway immune 
responses (Burgess et al., 2005; Ryzhov et al., 2004). IL-4 
and IL-13 reductions are also known to suppress IgE pro-
duction by B cells (Renauld, 2001; Steinke and Borish, 
2001; Zimmermann et al., 2003). According to our data, 
DA-9601 treatment reduced expressions of CD40 and 
CD40L molecules (Fig. 2), and productions of IL-4 and IL-
13 (Fig. 3) increased in lung tissues of OVA-induced mice. 
Therefore, the data suggest that DA-9601 reduces the pro-
duction of IgE antibody via probably suppressing Ig iso-
type class switching, which had been caused by inhibiting 
inflammatory cytokine production and by inhibiting co-
stimulatory molecules, CD40 and CD40L expressions. 
It is known that one of the predominant inflammatory 
cells recruited into asthmatic lung tissues is eosinophils, 
but neutrophils and macrophages have also been found to 
be elevated in the BAL fluids and lung tissues (McKay et 
al., 2004). Eosinophilia in asthmatic BAL fluids is associ-
ated with production of IL-5, which plays a critical role in 
the differentiation, infiltration, and activation of pulmo-
nary eosinophils (Wills-Karp and Karp, 2004). DA-9601 
also reduced the recruited eosinophils into BAL fluids 
(Table 2) and inflammatory cells into lung tissues (Fig. 
1A), mRNA and protein expression of IL-5 (Fig. 3) in 
OVA-induced lung tissues. Infiltration of inflammatory 
cells into airway tissues is also associated with expres-
sions of specific adhesion molecules (ICAM-1 and 
VCAM-1) enhanced by Th2-mediated cytokines such as 
IL-4 and TNF-α (Lim et al., 2003; Ohkawara et al., 1995; 
Steinke and Borish, 2001; Wills-Karp and Karp, 2004). 
Our data (Fig. 2C) are in agreement with these reports 
previously. Therefore, our data suggest that changes in the 
numbers of eosinophils in BAL fluids by DA-9601 may 
be directly caused by changes in IL-5 production, and by 
inhibiting the expression of VCAM-1 molecule. 
IL-13 induces goblet cell hyperplasia (Finkelman et al., 
2005), and TNF-α increases inflammatory cell infiltration 
(Banchereau et al., 1994; Ryzhov et al., 2004). DA-9601 
suppressed goblet cell hyperplasia (Fig. 1B), and also 
suppressed the mRNA and protein expressions of these 
cytokines (Fig. 3). These wide-ranging actions of DA-
9601 may result in relief from the symptoms of allergic 
asthma. Therefore, our data suggest that the inhibitory 
effect of DA-9601 shown in allergic mice may in part be 
mediated through its suppression of the production of 
cytokines and interaction of T/B cells, although we did 
not separate subtypes of T and B cells. 
Tissue remodeling is characterized by collagen deposi-
tion, airway smooth muscle hypertrophy, and goblet cell 
hyperplasia (Wills-Karp and Karp, 2004), and by MMPs 
produced via various factors such as TNF-α or IL-1β 
(Bond et al., 1998; Johnson et al., 2004). MMPs are ma-
jor proteolytic enzymes, and are actively involved in extra 
cellular matrix (ECM) turnover, due to their ability to 
cleave all proteins that contribute to the ECM. Recently, it 
was reported that alveolar macrophage-derived metallopro-
teinases and proteinases in sputum lead to tissue remodel-
ing in asthma (Bruce and Thomas, 2005; Ko et al., 2005). 
According to our data, DA-9601 inhibited inducible MMP-
9 and constitutive MMP-2 activities (Fig. 4) and TNF-α 
production (Fig. 3) produced by inflammatory cells as well 
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as goblet cell hyperplasia (Fig. 1B). Thereby, DA-9601 
reduces tissue remodeling due to inhibiting MMPs regu-
lated by TNF-α and goblet cell hyperplasia caused by IL-5. 
Previous studies have shown that the productions of 
many inflammatory cytokines are dependent on MAP 
kinase pathway (Lee et al., 2004b). Our data (Fig. 5A) 
suggest that DA-9601 inhibits the production of inflam-
matory cytokines via MAP kinase pathway in OVA-
induced allergic mouse lung tissues. 
The pleiotropic transcription factor NF-κB plays impor-
tant roles in the regulations of multiple genes. Allergic in-
flammation enhances NF-κB activity in human and animal 
lung tissues (Bureau et al., 2000; Desmet et al., 2004; Yang 
et al., 1998). The expressions of inflammatory proteins (IL-
4, IL-13, and TNF-α etc.), costimulatory and adhesion 
molecules, or extracellular molecules (MMPs and TIMPs 
etc.) are up-regulated in allergic airway inflammation. 
Moreover, the genes of these proteins are regulated by NF-
κB. In the present study, DA-9601 was also found to inhibit 
up-regulation of NF-κB activity in OVA-challenged mice 
(Fig. 5B). Therefore, the data suggest that DA-9601 inhib-
its productions of various cellular molecules as well as cy-
tokine productions by regulating NF-κB pathway. 
In conclusion, it is suggested that DA-9601 may be de-
veloped as an oral therapeutic agent for allergic diseases 
due to suppressing the airway allergic inflammation via 
regulating MAP kinases/NF-κB pathway. 
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